Table 2.
Association of KRAS testing and treatment with EGFR inhibitors among patients with mCRC.
| Treated with EGFR Inhibitors1 | Not Treated with EGFR Inhibitors | Total | |
|---|---|---|---|
| No KRAS Test | 89 (35%) | 671 (72%) | 760 (64%) |
| KRAS Test2 | 163 (65%) | 265 (28%) | 428 (36%) |
| WT | 136 (83%) | 110 (42%) | 246 (57%) |
| Mutation | 25 (15%) | 152 (57%) | 177 (42%)3 |
| Insufficient Sample | 2 (1%) | 3 (1%) | 5 (1%) |
1
Patient was treated with cetuximab or panitumumab at any time during the course of their clinical care.
2
A KRAS test was ordered as part of the patient's clinical care. WT = wild-type genotype, Mutation = any KRAS mutation for any codon tested, primarily codons 12 and 13 for most patients. Insufficient sample = a test was ordered but no KRAS genotype was reported.
3
40% had mutations in codon 12 or 13. An additional 2% had a mutation detected in codon 61. However, not all labs tested codon 61 as part of their KRAS sequencing protocol.